PATENT CLAIM ANALYSIS

Application Number: 16242315
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "253070"]

Abstract:
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

Claim (Index 44):
The composition of any one of  claims 37  to  40  being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 99.0
- Lexical Diversity: 1.63158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14252907', '10540577', '15176464', '10556600', '14639797']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7935008743499621
- 35 USC 102 Novelty (BERT): 0.6106948185570434
- Combined Prediction Score: 0.7752202687706703
- Mean Citation Score: 471.90887200000014
- Max Citation Score: 566.6824
- Similarity Product: 464.5230417775631

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test